On-demand video now available:
Webinar CDK4/6 Inhibition in Early and Advanced Breast Cancer 2025 – Updated Evidence, Controversy & Expert Debates
17.11.2025
The virtual continuing education event on CDK4/6 inhibitors in early and advanced breast cancer took place on Wednesday, October 29th, 2025, from 5:00 to 7:00 pm CET. A total of 106 participants from 12 countries joined the webinar, which was moderated by ABCSG President Professor Michael Gnant.
In Part 1, the focus was on CDK4/6 inhibitors in metastatic hormone receptor-positive breast cancer.
The session featured two complementary debate-style presentations:
Rupert Bartsch (ABCSG, Medical University of Vienna) argued for the motion that CDK4/6 inhibitors should remain the backbone of treatment for as long as possible, while Gabriel Rinnerthaler (ABCSG, Medical University of Graz) presented the counterarguments.
The session concluded with a stimulating discussion and audience Q&A moderated by Marija Balic (ABCSG, University of Pittsburgh School of Medicine, USA).
Part 2 centered on the adjuvant use of CDK4/6 inhibitors and the most recent trial data.
Christian Singer (ABCSG Vice President, Medical University of Vienna) presented the latest updates from the NATALEE trial, followed by Valentina Guarneri (Università di Padova, Italy) with new data from monarchE.
Patrick Neven (UZ Leuven, Belgium) discussed the clinical context and practical implications of adjuvant CDK4/6 inhibitor selection.
The event concluded with a panel discussion on updated evidence, ongoing controversies, and clinical consequences, chaired by Michael Gnant. All speakers were joined by additional discussants including Daniel Egle (ABCSG, Medical University of Innsbruck), Georg Pfeiler (ABCSG, Medical University of Vienna), Gunda Pristauz-Telsnigg (LKH Feldbach-Fürstenfeld), and Kathrin Strasser-Weippl (Klinik Ottakring, Vienna).
ABCSG would like to express its sincere thanks to Novartis and Lilly for their continued support.
It is particularly remarkable – and a source of great pride for ABCSG – that these two competitors in the field of CDK4/6 inhibition came together to support this educational event, emphasizing the shared commitment to advancing breast cancer care.
For those who missed the webinar, the on-demand video of the full session is now available in the → ABCSG Members Area
Teilen auf